The SureSelect Cancer All-In-One Solution includes an accelerated NGS library prep and target enrichment workflow and
advanced bioinformatics for data analysis and variant reporting.
The SureSelect Cancer All-In-One solution offers lung and solid tumor assays as well as a custom assay option.
You can define your specific genes of interest in an AIO custom assay.
The Agilent SureSelect Cancer All-In-One lung assay is a targeted NGS assay that analyzes a lung cancer panel of 20 genes relevant to NSCLC.
Starting from 50 ng of DNA, four types of genomic variants, including SNVs, indels, CNVs, and translocations, are detected.
This streamlined profiling of NSCLC also supports FFPE samples.
The target genes were selected to cover all genomic biomarkers in NSCLC, including the somatic variants associated with NSCLC in the guidelines
of the National Comprehensive Cancer Network (NCCN), the College of American Pathologists (CAP), and the European Society for Medical Oncology (ESMO).
The SureSelect Cancer All-In-One solid tumor assay is a streamlined tumor NGS assay.
This assay profiles a cancer panel of 98 genes clinically relevant to common solid tumor types for pertinent SNVs, indels, CNVs, and translocations.
Solid tumor types of interest include lung, breast, ovarian, colorectal, and prostate.
These genes were selected to cover the somatic variants associated with these solid tumor types in the guidelines of NCCN, CAP, and ESMO.